Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) toAdvance Clinical Research of Infectious Diseases
Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results.
United States United Kingdom Chris Orlando United Kingdom National Health Service Corporate Communications Research Use Only
Source: businesswireindia.com